This announcement is a separate document:
康辰药业监事会对《董事会关于2023年年报审计报告强调事项段涉及事项消除的专项说明》的意见
The board of supervisors of Beijing Konruns Pharmaceutical has opinions on the special statement concerning the elimination of matters related to the emphasis section of the audit report on the 2023 annual report by the board of directors.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.